Zai Lab Advances Three Oncology Candidates with AACR 2026 Data Presentations
Event summary
- Zai Lab will present data on three internally developed oncology candidates at AACR 2026, including zocilurtatug pelitecan (zoci), a DLL3-targeting ADC for small cell lung cancer.
- ZL-6201, an LRRC15-targeting ADC, and ZL-1222, a PD-1 and IL-12 immunocytokine, will also be featured in poster sessions.
- Zoci is on track to become Zai Lab’s first global oncology launch with three registration-enabling studies planned by the end of 2026.
- Poster presentations will cover intracranial activity of zoci in SCLC patients and preliminary results from a phase 1b/2 study.
The big picture
Zai Lab’s presentation of data on three oncology candidates underscores its commitment to developing innovative therapies for difficult-to-treat cancers. The company’s integrated U.S.-China development model aims to accelerate the advancement of these programs, potentially positioning Zai Lab as a key player in the global oncology market. The focus on DLL3-targeting ADCs and immunocytokines aligns with broader industry trends toward targeted and combination therapies.
What we're watching
- Clinical Efficacy
- How the intracranial activity data for zoci will position it as a potential new standard of care in previously treated ES-SCLC.
- Regulatory Pathway
- Whether Zai Lab can successfully navigate the three registration-enabling studies for zoci by the end of 2026.
- Market Differentiation
- The pace at which ZL-1222 can overcome PD-1 resistance while maintaining an acceptable safety profile.
Related topics